An investigator-sponsored, open-label, single dose, safety and tolerability study clinical study of a Durasert implant to treat severe OA of the knee.
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 28 Mar 2018
At a glance
- Drugs Dexamethasone (Primary)
- Indications Osteoarthritis
- Focus Adverse reactions
- 28 Mar 2018 According to an EyePoint Pharmaceuticals media release, pSivida Corp. changed its name to EyePoint Pharmaceuticals.
- 14 Dec 2017 According to pSivida media release, Dr. Mark P. Figgie, Chief of the Surgical Arthritis Service at Hospital for Special Surgery is the principal investigator of the study.
- 14 Dec 2017 Results published in the pSivida Media Release.